HDL cholesterol: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (Created page with "In physiology, '''HDL cholesterol''' ('''HDL''') is "cholesterol which is contained in or bound to high-density lipoproteins (HDL), including cholesterol esters and free ...") |
mNo edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[physiology]], '''HDL cholesterol''' ('''HDL''') is "cholesterol which is contained in or bound to high-density lipoproteins (HDL), including [[cholesterol ester]]s and free [[cholesterol]]."<ref>{{MeSH}}</ref> | In [[physiology]], '''HDL cholesterol''' ('''HDL''') is "cholesterol which is contained in or bound to high-density lipoproteins (HDL), including [[cholesterol ester]]s and free [[cholesterol]]."<ref>{{MeSH}}</ref> | ||
It is not clear whether insufficient HDL causes [[coronary artery disease]]<ref name="pmid22607825">{{cite journal| author=Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al.| title=Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. | journal=Lancet | year= 2012 | volume= | issue= | pages= | pmid=22607825 | doi=10.1016/S0140-6736(12)60312-2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22607825 }} </ref> and raising the HDL does not seem to reduce [[coronary artery disease]].<ref name="pmid22085343">{{cite journal| author=AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P et al.| title=Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. | journal=N Engl J Med | year= 2011 | volume= 365 | issue= 24 | pages= 2255-67 | pmid=22085343 | doi=10.1056/NEJMoa1107579 | pmc= | url= }} </ref> | It is not clear whether insufficient HDL causes [[coronary artery disease]]<ref name="pmid22607825">{{cite journal| author=Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al.| title=Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. | journal=Lancet | year= 2012 | volume= | issue= | pages= | pmid=22607825 | doi=10.1016/S0140-6736(12)60312-2 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22607825 }} </ref> and raising the HDL does not seem to reduce [[coronary artery disease]].<ref name="pmid22085343">{{cite journal| author=AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P et al.| title=Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. | journal=N Engl J Med | year= 2011 | volume= 365 | issue= 24 | pages= 2255-67 | pmid=22085343 | doi=10.1056/NEJMoa1107579 | pmc= | url= }} </ref> | ||
Low HDL is part of [[hypoalphalipoproteinemia]]. | |||
The HDL cholesterol efflux capacity, "the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport" may be a more important biomarker than the HDL level at predicting cardiovascular events.<ref name="pmid25404125">{{cite journal| author=Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE et al.| title=HDL cholesterol efflux capacity and incident cardiovascular events. | journal=N Engl J Med | year= 2014 | volume= 371 | issue= 25 | pages= 2383-93 | pmid=25404125 | doi=10.1056/NEJMoa1409065 | pmc=PMC4308988 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25404125 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
Latest revision as of 16:00, 24 August 2024
In physiology, HDL cholesterol (HDL) is "cholesterol which is contained in or bound to high-density lipoproteins (HDL), including cholesterol esters and free cholesterol."[1]
It is not clear whether insufficient HDL causes coronary artery disease[2] and raising the HDL does not seem to reduce coronary artery disease.[3]
Low HDL is part of hypoalphalipoproteinemia.
The HDL cholesterol efflux capacity, "the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport" may be a more important biomarker than the HDL level at predicting cardiovascular events.[4]
References
- ↑ Anonymous (2024), HDL cholesterol (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al. (2012). "Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.". Lancet. DOI:10.1016/S0140-6736(12)60312-2. PMID 22607825. Research Blogging.
- ↑ AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P et al. (2011). "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.". N Engl J Med 365 (24): 2255-67. DOI:10.1056/NEJMoa1107579. PMID 22085343. Research Blogging.
- ↑ Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE et al. (2014). "HDL cholesterol efflux capacity and incident cardiovascular events.". N Engl J Med 371 (25): 2383-93. DOI:10.1056/NEJMoa1409065. PMID 25404125. PMC PMC4308988. Research Blogging.